<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="1-part\PMC6734352\results\search\drugs\results.xml">
  <result pre="Administration (FDA): matrix-2 (M2) protein ion channel blockers (such as" exact="amantadine" post="and rimantadine) and neuraminidase (NA) inhibitors (such as zanamivir"/>
  <result pre="as amantadine and rimantadine) and neuraminidase (NA) inhibitors (such as" exact="zanamivir" post="and oseltamivir) [7]. However, during the last years, there"/>
  <result pre="(Merck, Germany), 2 mM L-glutamine (Merck, Germany), and 100 U/ml penicillin and 100 μg/ml" exact="streptomycin" post="sulfate (Sigma-Aldrich, USA). Influenza A/Puerto Rico/8/34 (H1N1; PR8) was"/>
  <result pre="in this experiment. This assay was also carried out for" exact="oseltamivir" post="and soluble polyethylene glycol. At the indicated time of"/>
  <result pre="Cytotoxicity assay Cytotoxic effects of ZnO-NPs, ZnO-PEG-NPs, polyethylene glycol, and" exact="oseltamivir" post="on MDCK-SIAT1 cells were determined using the MTT assay."/>
  <result pre="MTT assay. As shown in Fig. 4, polyethylene glycol and" exact="oseltamivir" post="did not show significant cytotoxic effects toward MDCK-SIAT1 cells."/>
  <result pre="Cytotoxicity of ZnO-NPs (a), ZnO-PEG-NPs (b), polyethylene glycol (c), and" exact="oseltamivir" post="(d) on MDCK-SIAT1 cells. * Statistically significant (p &amp;lt; 0.05). **"/>
  <result pre="in 1.2 log10 TCID50 reduction (P &amp;lt; 0.0001). In our experiments," exact="oseltamivir" post="was used as a positive control for comparison of"/>
  <result pre="the post-exposure antiviral activity of ZnO-NPs, ZnO-PEG-NPs, polyethylene glycol, and" exact="oseltamivir" post="on the titer of H1N1 influenza virus by TCID50"/>
  <result pre="that the production of influenza virus was completely inhibited by" exact="oseltamivir" post="at the concentration of 75 μg/mL. Furthermore, the inhibition rate"/>
  <result pre="Lin et al., antiviral properties of selenium nanoparticles (SeNPs) and" exact="zanamivir" post="modified selenium nanoparticles (Se@ZNV) against H1N1 influenza virus investigated,"/>
  <result pre="has a higher antiviral activity compared to the SeNPs and" exact="zanamivir" post="alone [27]. Similarly, Li et al. conducted a study"/>
  <result pre="conducted a study to investigate antiviral capabilities of SeNPs and" exact="oseltamivir" post="surface-modified SeNPs (Se@OTV) against H1N1 influenza virus [28]. Their"/>
  <result pre="and sialic acid receptor on the host cell. Oseltamivir and" exact="zanamivir" post="are sialic acid analogues and neuraminidase inhibitors which prevents"/>
  <result pre="studies conducted by Lin et al. and Li et al.," exact="oseltamivir" post="and zanamivir modified selenium nanoparticles were used for evaluation"/>
  <result pre="by Lin et al. and Li et al., oseltamivir and" exact="zanamivir" post="modified selenium nanoparticles were used for evaluation of anti-influenza"/>
  <result pre="9.NguyenJTSmeeDFBarnardDLJulanderJGGrossMde JongMDet al.Efficacy of combined therapy with amantadine, oseltamivir, and" exact="ribavirin" post="in vivo against susceptible and amantadine-resistant influenza a virusesPLoS"/>
  <result pre="al.Inhibition of H1N1 influenza virus by selenium nanoparticles loaded with" exact="zanamivir" post="through p38 and JNK signaling pathwaysRSC Adv2017756352903529610.1039/C7RA06477B 28.LiYLinZGuoMXiaYZhaoMWangCet al.Inhibitory"/>
  <result pre="pathwaysRSC Adv2017756352903529610.1039/C7RA06477B 28.LiYLinZGuoMXiaYZhaoMWangCet al.Inhibitory activity of selenium nanoparticles functionalized with" exact="oseltamivir" post="on H1N1 influenza virusInt J Nanomedicine201712573310.2147/IJN.S14093928848350 29.MittalNMedhiBThe bird flu:"/>
 </snippets>
</snippetsTree>
